Compare CODA & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CODA | SPRO |
|---|---|---|
| Founded | 1994 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 155.4M | 124.5M |
| IPO Year | 2007 | 2017 |
| Metric | CODA | SPRO |
|---|---|---|
| Price | $14.56 | $2.54 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 265.8K | 240.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 15.62 | N/A |
| EPS | ★ 0.37 | N/A |
| Revenue | $20,316,161.00 | ★ $47,977,000.00 |
| Revenue This Year | $16.42 | N/A |
| Revenue Next Year | $14.43 | N/A |
| P/E Ratio | $45.76 | ★ N/A |
| Revenue Growth | ★ 4.98 | N/A |
| 52 Week Low | $5.76 | $0.51 |
| 52 Week High | $17.28 | $3.09 |
| Indicator | CODA | SPRO |
|---|---|---|
| Relative Strength Index (RSI) | 54.66 | 68.12 |
| Support Level | $7.25 | $2.15 |
| Resistance Level | $14.89 | $2.70 |
| Average True Range (ATR) | 1.04 | 0.09 |
| MACD | 0.10 | 0.03 |
| Stochastic Oscillator | 31.76 | 98.11 |
Coda Octopus Group Inc develops underwater technologies and equipment for imaging, mapping defense, and survey applications. The company operates in three distinct business segments: the Marine Technology business, Acoustic Sensors and Material Business and the Defense Engineering Services Business. Its geographical segments are the Americas, Europe, Australia/Asia, and the Middle East/Africa. The majority of revenue is derived from the Products segment.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.